microbicide

In a recent New York Times article, Celia Dugger reports on encouraging results from two studies on interventions that help women in South Africa and Malawi reduce their risk of HIV infection. The first study found that women using a vaginal microbicidal gel were 39% less likely to contract HIV than those using a placebo. It has been published in Science, and its authors write in their abstract: The CAPRISA 004 trial assessed effectiveness and safety of a 1% vaginal gel formulation of tenofovir, a nucleotide reverse transcriptase inhibitor, for the prevention of HIV acquisition in women. A…